Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

CHIP/CCUS Natural History Protocol

25 september 2026 uppdaterad av: National Heart, Lung, and Blood Institute (NHLBI)

Undersökning av den naturliga utvecklingen av klonal hematopoiesis av obestämd potential och klonal cytopeni av obestämd betydelse.

Background:

Clonal Hematopoiesis of Indeterminate Potential (CHIP) is a change in a person s DNA that can increase a person s risk of developing blood cancers or cardiovascular disease. CHIP occurs mostly occurs in older people. Clonal cytopenia of undetermined significance (CCUS) occurs when one or more blood cell types is lower than it should be and is associated with a change in their DNA. Researchers want to learn more about how CHIP and CCUS progress.

Objective:

To examine the natural history of people in a study of CHIP and CCUS to (1) verify the association of myeloid somatic mutations with atherosclerosis and blood cancers, and (2) find new potential clinical associations.

Eligibility:

Adults 18 and older with CHIP with a somatic pathogenic variant associated with blood cancers. Adults with CCUS are also needed.

Design:

Potential participants will be screened with gene testing. For this, they will give a blood sample. They will also be enrolled in NHLBI screening protocol #97-H-0041. Those who pass this screening will visit the NIH Clinical Center for more screening tests. For this, they will give a blood sample. They will have a physical exam. They will give their medical history. They may give a urine sample. Those with CCUS will have bone marrow taken.

Eligible participants will give blood and urine samples. Their heart activity will be monitored and tested. The arteries in their neck will be assessed using ultrasound. They will have liver and heart scans. They will have a bone mineral density scan. They will have lung function tests. They will have the inside of their cheek swabbed or have a skin punch biopsy. They will have the option to have advanced scans done of their heart and full body but this is not required.

Participants will have yearly follow-up visits for 10 years. They will repeat the above procedures every 1-3 years depending on the procedure.

Studieöversikt

Detaljerad beskrivning

Clonal Hematopoiesis of Indeterminate Potential (CHIP) has been defined as the presence of a somatic pathogenic variant associated with hematological malignancy, with an allele fraction of at least 2%, without morphological evidence of bone marrow dysplasia or neoplasia. Such variants are small, occur in leukocytes and are found in a substantial proportion of the healthy aging population using next generation sequencing (NGS). They are thought to represent a pre-neoplastic phase of hematological malignancy, particularly myeloid disorders such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). They are considered by some to be analogous to monoclonal B cell lymphocytosis (MBL), or monoclonal gammopathy of uncertain significance (MGUS) as precursors for chronic lymphocytic leukemia (CLL) and myeloma respectively, and, with a similar rate of progression of 0.5%-1% per year.

CHIP is strongly associated with advancing age with a prevalence of up to 10% in those >65 years of age compared to 1% in those <50 years of age, and has also been associated with an increased atherosclerotic risk, and an increase in overall mortality. Despite this association, most people with CHIP are denoted healthy and do not progress to hematological malignancy. Those with low blood counts in association with a - termed clonal cytopenias of undetermined significance (CCUS) - do show a significantly higher rate of progression to myeloid malignancy, more analogous to patients with low risk MDS, though they are currently not classified as such as they lack the morphological dysplasia or defining chromosomal abnormalities.

The optimal follow-up and management of CHIP and CCUS is not yet established - evidence has suggested that factors such as which specific variant, how many variants are present, and the frequency at which these variants increase can help us to delineate high and low risk status. Some recent data has shown that the presence of CHIP is associated with increased levels of inflammation. In depth, investigation should provide further insight into the pathogenesis and progression of this process. The establishment of a natural history protocol will allow patients with CHIP and CCUS to be followed prospectively in a clinical setting. This protocol will have many collaborators from different institutes providing expertise including National Human Genome Research Institute (NHGRI), National Heart, Lung and Blood Institute (NHLBI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and the Department of Laboratory Medicine (DLM).

Studietyp

Observationell

Inskrivning (Beräknad)

306

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • Maryland
      • Bethesda, Maryland, Förenta staterna, 20892
        • Rekrytering
        • National Institutes of Health Clinical Center
        • Kontakt:
          • For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
          • Telefonnummer: TTY dial 711 800-411-1222
          • E-post: ccopr@nih.gov

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 99 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Primary Clinical

Beskrivning

  • Participants with Clonal Hematopoiesis of Indeterminate Significance (CHIP):

INCLUSION CRITERIA:

  • Greater than or equal to 18 years of age
  • Willingness and capacity to provide written informed consent
  • Presence of a somatic pathogenic variant associated with hematological malignancy
  • Variant allele fraction of greater than or equal to 2% in at least one identified somatic pathogenic variant

EXCLUSION CRITERIA:

  • Known diagnosis of a hematological malignancy or bone marrow failure syndrome (excluding MGUS or MBL)

  • Presence of a cytopenia:

    --Hemoglobin, <10 g/dL; platelet count, <100 X 10^9 /L; or absolute neutrophil count, <1.5 X 10^9 /L

  • Pregnant at the time of recruitment

Participants with Clonal Cytopenia of Uncertain Significance (CCUS):

INCLUSION CRITERIA:

  • Greater than 18 years of age
  • Willingness and capacity to provide written informed consent
  • Presence of a somatic pathogenic variant associated with hematological malignancy without morphological evidence of

myelodysplasia and without a MDS defining cytogenetic abnormality

  • Variant allele fraction of greater than or equal to 2% in at least one identified somatic pathogenic variant

  • Bone marrow aspirate and biopsy excluding hematological malignancy and MDS

  • Presence of a cytopenia for >30 days

    • Hemoglobin, <10 g/dL; platelet count, <100 X10^9 /L; or absolute neutrophil count, <1.5 X10^9 /L
    • At least 2 CBCs documented in a non-hospitalized patient at least 3 days apart

EXCLUSION CRITERIA:

  • Known diagnosis of a hematological malignancy or bone marrow failure syndrome (excluding MGUS or MBL)

  • Morphological evidence of dysplasia on bone marrow aspirate / biopsy 10% dysplastic cells in any hematopoietic lineage

  • Ringed sideroblasts >15%

  • Presence of MDS defining cytogenetic abnormality

    • Del(7q)
    • del(5q)
    • 17q or t(17p)
    • Del(13q)
    • del(11q)
    • del(12p) or t(12p)
    • del(9q)
    • idic(X)(q13)
    • t(11;16)
    • t(3;21)
    • t(1;3)
    • t(2;11)
    • inv(3)/t(3;3)
  • t(6;9)

    --Note: As a sole cytogenetic abnormality in the absence of morphological criteria, gain of chromosome 8, del(20q) and loss of chromosome Y are not considered definitive evidence of MDS.

  • Alternate hematological diagnosis causing cytopenia

  • Pregnant at time of recruitment

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
CCUS

All participants meeting the criteria for CCUS

CHIP

Subjects will be split into five cohorts depending on specific mutations

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Verify the previously studied association of myeloid somatic mutations with hematological malignancy
Tidsram: 10 years

Association of myeloid somatic mutations with hematological malignancy

10 years
Verify the previously studied association of myeloid somatic mutations with atherosclerosis
Tidsram: 10 years

Association of myeloid somatic mutations with atherosclerosis

10 years
Immune response
Tidsram: 10 years

Assessing immune response by measuring markers of inflammation

10 years
Examine potential new clinical associations
Tidsram: 10 years

New clinical associations

10 years
Development of cytopenia, hematological malignancy, and the size and stability of leucocyte somatic mutations
Tidsram: 10 years

Cytopenia, hematological malignancy, and the size and stability of leucocyte somatic mutations

10 years

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Relationship between CHIP/CCUS and chronic viral infections such as CMV, EBV, HSV, HIV, Hepatitis B and Hepatitis C
Tidsram: 10 years

To establish whether there is a relationship between CHIP/CCUS and chronic viral infections such as CMV, EBV, HSV, HIV, Hepatitis B and Hepatitis C

10 years
Relationship between CHIP/CCUS and atherosclerosis, diabetes, and metabolic syndrome
Tidsram: 10 years

To establish whether there is a relationship between CHIP/CCUS and atherosclerosis, diabetes, and metabolic syndrome

10 years
Correlation between CHIP/CCUS and vitamin levels
Tidsram: 10 years

To establish whether there is a correlation between CHIP/CCUS and vitamin levels

10 years
Correlation between CHIP/CCUS and chronic renal impairment
Tidsram: 10 years

To establish whether there is a correlation between CHIP/CCUS and chronic renal impairment

10 years
Correlation between CHIP/CCUS and chronic lung disease
Tidsram: 10 years

To establish whether there is a correlation between CHIP/CCUS and chronic lung disease

10 years
Correlation between CHIP/CCUS and chronic liver disease
Tidsram: 10 years

To establish whether there is a correlation between CHIP/CCUS and chronic liver disease

10 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Fernanda Gutierrez Rodrigues, National Heart, Lung, and Blood Institute (NHLBI)

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

3 mars 2020

Primärt slutförande (Beräknad)

15 september 2033

Avslutad studie (Beräknad)

15 september 2033

Studieregistreringsdatum

Först inskickad

24 september 2019

Först inskickad som uppfyllde QC-kriterierna

24 september 2019

Första postat (Faktisk)

25 september 2019

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

28 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

25 september 2026

Senast verifierad

24 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

IPD-planbeskrivning

It is not yet known.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera